购物车
- 全部删除
- 您的购物车当前为空
Serdemetan (JNJ-26854165) 是一种 HDM2泛素连接酶拮抗剂,能诱导 p53野生型细胞的早期凋亡。
为众多的药物研发团队赋能,
让新药发现更简单!
Serdemetan (JNJ-26854165) 是一种 HDM2泛素连接酶拮抗剂,能诱导 p53野生型细胞的早期凋亡。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 233 | 现货 | |
2 mg | ¥ 329 | 现货 | |
5 mg | ¥ 538 | 现货 | |
10 mg | ¥ 847 | 现货 | |
25 mg | ¥ 1,630 | 现货 | |
50 mg | ¥ 2,920 | 现货 | |
100 mg | ¥ 4,180 | 现货 | |
500 mg | ¥ 8,820 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 589 | 现货 |
产品描述 | Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity. |
靶点活性 | REH cells:0.44 μM, OCI-AML3 cells:0.24 μM, MOLM-13:0.33 μM, NALM6:0.32 μM |
体外活性 | 在实体移植瘤和ALL移植瘤种,口服 JNJ-26854165(20 mg/kg)能够使EFS分布显现显著差异. |
体内活性 | 在白血病细胞系中,JNJ-26854165能够抑制细胞生长,并且诱导细胞凋亡,对于OCI-AML-3(IC50=0.24 μM), MOLM-13(IC50=0.33 μM),NALM-6(IC50=0.32 μM)和REH(IC50=0.44 μM)均有抑制作用。在人类癌细胞系中(H460,A549,p53-WT-HCT116,和p53-null-HCT116),JNJ-26854165能够抑制细胞增殖。 |
细胞实验 | Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK(Only for Reference) |
别名 | N-[2-(1H-吲哚-3-基)乙基]-N'-(4-吡啶基)-1,4-苯二胺, JNJ-26854165 |
分子量 | 328.41 |
分子式 | C21H20N4 |
CAS No. | 881202-45-5 |
Smiles | C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1 |
密度 | 1.274g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
溶解度信息 | Ethanol: 2 mg/mL (6.08 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 50 mg/mL (152.25 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容